Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational

MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

NCT05058729
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 16, 2026, 8:51 PM EDT
Terminated No phase listed Observational

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

NCT00618319
View directory record Official record
Conditions
GIST
Interventions
BIIB021
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Encinitas, California • Santa Monica, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

NCT02829541
View directory record Official record
Conditions
Systemic Lupos Erythematosus, SLE
Interventions
BIIB068, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 16, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

NCT00588822
View directory record Official record
Conditions
Precancerous Condition
Interventions
Rituximab
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 16, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 16, 2026, 8:51 PM EDT
Terminated No phase listed Observational

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976
View directory record Official record
Conditions
Relapsing Forms of MS
Interventions
Diroximel Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

NCT00599274
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
8
States / cities
Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

NCT01420458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Experimental
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

NCT04593121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB107, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational

Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis

NCT01749943
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational

TYSABRI Global Observational Program in Safety

NCT00477113
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
2,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

NCT00955396
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1014802, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 16, 2026, 8:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

NCT01244139
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

NCT02292537
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 12 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 16, 2026, 8:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 16, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

NCT02332798
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 16, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 16, 2026, 8:51 PM EDT